SCYNEXIS, Inc. SCYX 深 滬
等待開盤 04-03 09:30:00 美东时间
0.8879
0.000
-0.05%
華盛通- 最 高0.90
- 今 開0.88
- 成交量 25.86万股
- 最 低 0.85
- 昨 收 0.8883
- 總市值 3965.70万
- 52周最高 1.31
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 0.565
- 委 比 58.73%
- 總股本 4466.38万
- 歷史最高 150.00
- 量 比 0.10
- 振 幅 5.63%
- 歷史最低 0.565
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SCYNEXIS Agrees With Poxel To Acquire PXL-770; $8M Upfront, Up To $188M Milestones
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company focused on developing innovative new therapies to address severe rare diseases, today announced that it has entered into a definitive agreement with Poxel S.A.
03-31 18:43
SCYNEXIS Announces $40.0 Million Private Placement
SCYNEXIS, Inc. has entered into a private placement agreement with institutional and accredited investors, anticipate gross proceeds of approximately $40 million upfront, with an additional $52.2 million if Common Warrants are exercised, subject to stockholder approval. The company will issue 34.75 million common shares, 8.75 million pre-funded warrants, and 43.5 million common warrants. The financing includes participation from new and existing ...
03-31 10:45
SCYNEXIS Says On March 15, 2026 Co Received FDA Orphan Drug Designation For Brexafemme (Triterpenoid Antifungal) For Treatment Of Invasive Candidiasis
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1123525
03-17 00:18
SCYNEXIS Q4 Earnings Assessment
The Q4 earnings report for SCYNEXIS (NASDAQ:SCYX) was released on Wednesday, Ma...
03-05 05:48
SCYNEXIS Q4 EPS $0.25 Beats $0.13 Estimate, Sales $18.646M Beat $8.100M Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.13 by 96.85 percent. This is a 377.78 percent increase over losses of $(0.09) per share from the same
03-05 05:40
SCYNEXIS Says First Participants Dosed In Phase 1 SAD And MAD Trial Evaluating IV Of Second-Gen Triterpenoid Antifungal Therapy, SCY-247; Trial Results Expected In 2026
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the first participants have been
02-26 21:26
SCYNEXIS Announces Upcoming Presentations Highlighting Data On Second-Gen Fungerp Drug Candidate, SCY-247, At 2026 IMARI
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on
01-28 21:05
SCYNEXIS Granted FDA's Qualified Infectious Disease Product, Fast Track Designations For Second-Generation Triterpenoid Antifungal Therapy SCY-247
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration
01-21 21:02
SCYNEXIS Receives Nasdaq Extension To Regain Bid Price Compliance By June 15, 2026
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional
2025-12-22 21:12
Trevi Therapeutics appoints new CFO
Trevi Therapeutics (TRVI) named David Hastings as its next chief financial officer, effective January 6, 2026. Hastings prior roles include CFO positions at Arbutus, Unilife, and Incyte. Hastings curr...
2025-12-04 20:43
